After a thorough and comprehensive review of proposals received from suppliers of viral marker testing platforms and assays, CTS has decided to convert to the Ortho VERSEIA Integrated Processor (VIP) viral marker testing platform and associated assays in January 2021. An exact conversion date will be provided when available. We are confident that the VERSIA system will allow us to continue delivering on our commitment to support our clients in their life-saving mission.
Read all about it on the Communication page by clicking this link: Communications
On June 13, 2019, CTS provided information regarding the manufacturer’s discontinuation of HIV...
CTS Spotlight at 2018 AABB Annual Meeting Sunday, October 14, 2018 at 1:30 PM: Scientific Oral ...
This is the first update to the original CTS communication distributed on July 6th. As previously co...
CTS originally communicated that Tampa will convert from the current Grifols Ultrio Plus NAT triplex...
CTS will be transitioning to a new sFTP server for clients who send test request and/or receive...
On August 9, 2019, the new CTS Laboratory Information System was successfully implemented in St...